USA flag logo/image

An Official Website of the United States Government

A2a Adenosine Receptors and Equine Sepsis

Award Information

Agency:
Department of Agriculture
Branch:
N/A
Award ID:
61989
Program Year/Program:
2003 / SBIR
Agency Tracking Number:
2003-00471
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ADENOSINE THERAPEUTICS, LLC
310 FOURTH STREET NE SUITE 201 CHARLOTTESVILLE, VA 22902
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2003
Title: A2a Adenosine Receptors and Equine Sepsis
Agency: USDA
Contract: 2003-33610-13038
Award Amount: $75,000.00
 

Abstract:

NON-TECHNICAL SUMMARY: This is a phase I SBIR proposal by Adenosine Therapeutics for 6 months of support to synthesize and evaluate novel compounds as agonists of equine A2A adenosine receptors. Some of these compounds have been found to be very effective in reducing rodent mortality form endotoxin or from E. coli-induced sepsis. Circulating endotoxin (lipopolysaccharide) is correlated with the probability of death in horses of all ages (colic in adult horses; septicemia in neonates). These studies have the potential of producing a new therapy of horse sepsis and colic that are devastating equine diseases. Our goal is to develop new therapies for the treatment of equine sepsis and colic. Such new therapies have excellent commercial potential since these diseases occur in tens of thousands of horses annually and these animals have a poor prognosis. Preliminary studies in rodents indicate that this new type of therapy is highly effective in reducing the severity of septic inflammation and drastically reduces the frequency of mortality.

Principal Investigator:

Robert Thompson
4349519484
rdt@adenrx.com

Business Contact:

Robert S. Capon
CEO
4342209400
rob@adenrx.com
Small Business Information at Submission:

Adenosine Therapeutics, LLC
300 Preston Avenue, 5th Floor Charlottesville, VA 22902

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No